0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover0.00%IV-60.32%PremiumOct 18, 2024Expiry Date3.80Intrinsic Value100Multiplier17DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.07Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Sight Sciences Stock Discussion
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
Sight Sciences announced the publication of twelve-month results from the SAHARA trial, showing clinically meaningful improvements in dry eye disease for patients who switched from Restasis to the TearCare treatment. Phase 2 of the trial included 163 patients who had used Rest...
NEWS
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
Sight Sciences, Inc. (Nasdaq: SGHT) announces results of a large-scale MIGS study comparing three leading technologies in glaucoma patients. OMNI technology shows significant IOP and...
In the realm of ophthalmology, groundbreaking advancements are not just welcomed; they are necessary. As we navigate through the complexities of eye diseases, companies like Sight Sciences are leading the charge with innovative solutions that promise not only relief but also a renewed hope for millions globally. Rec...
Gapping up
$Apple (AAPL.US)$ stock rose 0.2% ahead of the iPhone maker's latest hardware update in California later in the session, which is expected to see the launch of the iPhone 15.
$Boeing (BA.US)$ stock rose 0.1% after SMBC Aviation Capital, the world's second largest aircraft leasing firm, said it had concluded an order for 25 Boeing 737 MAX aircraft in a deal worth more than $3.7 billion a...
No comment yet